Is metformin hcl extended release
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Metformin HCl Extended Release: A Comprehensive Overview
Introduction to Metformin HCl Extended Release
Metformin hydrochloride (HCl) is a widely used medication for managing type 2 diabetes mellitus. The extended-release (ER) formulation of metformin HCl has been developed to improve patient compliance, reduce gastrointestinal side effects, and provide sustained blood glucose control .
Manufacturing and Formulation Techniques
Continuous Twin Screw Granulation
The transition from batch to continuous manufacturing processes for metformin HCl ER formulations has been explored to enhance production efficiency. Studies have shown that using hydrophilic polymers like hydroxypropyl methylcellulose (HPMC) in continuous twin screw granulation results in granules with better size distribution and strength compared to those produced with distilled water as a binder. This method ensures that the granules meet the necessary size and flowability requirements for tablet formation, with no significant differences in tablet properties between batch and continuous processes.
Hydrophilic and Hydrophobic Polymers
The development of metformin HCl ER tablets often involves the use of hydrophilic polymers such as Methocel K4M and K100, which control the drug release rate effectively. These formulations have shown a gradual release profile, with significant drug release over a 10-hour period. Additionally, combining hydrophobic carriers like stearic acid with hydrophilic polymers such as polyethylene oxide (PEO) has been found to control the initial rapid release of metformin, with melt granulation being more effective than direct compression.
Efficacy and Safety of Metformin HCl Extended Release
Glycemic Control
Clinical trials have demonstrated that metformin HCl ER is as effective as the immediate-release (IR) formulation in reducing HbA1c levels and fasting plasma glucose (FPG) . In a 24-week study, patients receiving 2,000 mg/day of metformin ER showed a greater reduction in HbA1c levels compared to those on the IR formulation, indicating superior glycemic control with higher doses of the ER formulation.
Gastrointestinal Tolerability
One of the primary advantages of the ER formulation is its improved gastrointestinal tolerability. Studies have shown that patients on metformin ER experience fewer gastrointestinal side effects, such as nausea and diarrhea, compared to those on the IR formulation . This improved tolerability is likely due to the slower and more controlled release of the drug, which reduces the peak plasma concentrations that can cause gastrointestinal distress.
Patient Compliance
The once-daily dosing regimen of metformin ER significantly enhances patient compliance compared to the twice-daily regimen required for the IR formulation. This convenience, coupled with the reduced side effects, makes metformin ER a preferred choice for many patients .
Special Applications
Preterm Pre-eclampsia
Recent research has explored the use of metformin ER in prolonging gestation in women with preterm pre-eclampsia. A randomized, double-blind, placebo-controlled trial indicated that metformin ER could extend gestation by a median of 7.6 to 11.5 days compared to placebo, providing a potential new therapeutic application for this formulation.
Conclusion
Metformin HCl extended-release formulations offer significant benefits over immediate-release formulations, including improved patient compliance, better gastrointestinal tolerability, and sustained glycemic control. Advances in manufacturing techniques and formulation strategies continue to enhance the efficacy and safety of metformin ER, making it a valuable option for managing type 2 diabetes and potentially other conditions like preterm pre-eclampsia.
Sources and full results
Most relevant research papers on this topic